Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
Communications Fellowship based in Cambridge, Massachusetts. About Sarepta Therapeutics Sarepta is a global biotechnology company on an urgent mission to engineer precision genetic medicine for rare diseases
-
functional profiles, host genetic variation, and behavioral phenotypes from one of the world's largest mouse systems genetics resources. These models will leverage over a decade of data generated through the
-
patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced
-
status or related conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law
-
conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law. Responsibilities Regulatory
-
approach using a variety of cognitive and cognitive neuroscience approaches (e.g. behavioral, psychophysical, neuropsychological, physiological, imaging, pharmacological, genetic, and computational methods
-
conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law. Responsibilities The
-
more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with
-
more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA